36
Participants
Start Date
July 31, 2006
Primary Completion Date
June 30, 2008
Study Completion Date
August 31, 2008
Verteporfin Photodynamic Therapy (Low Fluence) and bevacizumab
"Bevacizumab 1.25 mg with verteporfin at Low Fluence (300 mW/cm2 delivered for 83 seconds \[light dose of 25 J/cm2\]) Photodynamic Therapy.~Treatment at Baseline visit, followed by an as needed basis. Assessments monthly for bevacizumab and at 3-month intervals for combination therapy with verteporfin or sham."
Verteporfin Photodynamic Therapy (Very Low Fluence) and bevacizumab
"Bevacizumab 1.25 mg with verteporfin at Low Fluence (150 mW/cm2 delivered for 83 seconds \[light dose of 12.5 J/cm2\]) Photodynamic Therapy.~Treatment at Baseline visit, followed by an as needed basis. Assessments monthly for bevacizumab and at 3-month intervals for combination therapy with verteporfin or sham."
Verteporfin Photodynamic Therapy (SHAM) and bevacizumab
"Bevacizumab with SHAM (150 mW/cm2 delivered for 83 seconds \[light dose of 12.5 J/cm2\]) Photodynamic Therapy.~Treatment at Baseline visit, followed by an as needed basis. Assessments monthly for bevacizumab and at 3-month intervals for combination therapy with verteporfin or sham."
Vancouver General Hospital Eye Care Centre (UBC), Vancouver
University of British Columbia
OTHER